Biocon’s subsidiary Biocon Pharma has received the Food and Drug Administration’s permission for norepinephrine bitartrate injection (4 mg/4 ml, 1 mg/ml) in a single-dose vial, the company ...

Urodynamics plus comprehensive clinical assessment (CCA) showed no superiority over CCA alone in treating women with refractory overactive bladder symptoms. CCA for female incontinence offered ...

The MD-6000 Bladder Scanner is used regularly by urologists, primary care physicians (internal medicine/family practice), gynecologists, hospital units, long term/extended care facilities and in ...

Stellantis said on Thursday it was temporarily laying off 900 workers at five U.S. facilities after President Donald Trump’s tariffs were announced, and temporarily pausing production at an ...

The health of Pope Francis has led to renewed interest in a 900-year-old book known as "The Prophecy of the Popes" (“Prophetia Sancti Malachiae Archiepiscopi, de Summis Pontificibus” - or ...

With an extended scan depth, ultra-fast accuracy, and a lightweight, ergonomic design, the i900 classic continues Medit's commitment to innovation in digital dentistry. This new addition is ...

Biocon Ltd share price was down by -5.19% from the previous closing price of ₹345.75. Who are peers of Biocon Ltd? The peers of Biocon Ltd are Sun Pharmaceutical Industries Ltd, Divis ...

This guide provides you with all the information you need at your first doctor’s visit for an overactive bladder. Read on to find out more. An overactive bladder involves the strong urge to pass ...

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

March 11, 2025 /PRNewswire/ -- Medit (www.medit.com), a global leader in digital dentistry, is set to unveil a new addition to its i900 intraoral scanner lineup on March 25. Designed to enhance ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...